Companies Edgewise Therapeutics
Edgewise Therapeutics (EWTX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Edgewise Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers47th pct.Of 17 peer CEOs
CEO pay, last three years
- $3,975,855FY2023
- $7,601,200FY2024
- $7,359,546FY2025
CEO total pay was $7,359,546 in fiscal 2025, down from $7,601,200 in fiscal 2024.
FY2025: salary $670,000 · stock awards $1,171,625 · option awards $5,041,621
Executives and directors
Alan Russell · ExecutiveBehrad Derakhshan · COOR. Michael Carruthers · CFOKevin Koch · CEORobert Blaustein · Chief Development OfficerMichael Nofi · CFOJoanne Donovan · Chief Medical OfficerArlene M. Morris · Independent DirectorBadreddin Edris, Ph.D · Independent DirectorChristopher Martin · Independent DirectorJonathan C. Fox, M.D., Ph.D · Independent DirectorJonathan Root, M.D · Independent DirectorLaura Brege · Independent DirectorPeter Thompson, M.D · Director
Frequently asked questions
Who was the highest-paid executive at Edgewise Therapeutics in fiscal 2025?
As disclosed, Kevin Koch (President and Chief Executive Officer) was the highest-paid executive at Edgewise Therapeutics in fiscal 2025, with total compensation of $7,359,546.
How does Edgewise Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Kevin Koch's total compensation ranked at the 47th percentile of Edgewise Therapeutics's disclosed peer group.
How did shareholders vote on Edgewise Therapeutics's executive compensation?
As disclosed, 96.14% of shareholders supported Edgewise Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Edgewise Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Edgewise Therapeutics reported total board compensation of $364,712 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Koch | $670,000 | — | $1,171,625 | $5,041,621 | $462,300 | — | $14,000 | $7,359,546 |
| President and Chief Executive Officer | ||||||||
| Robert Blaustein | 525,000 | — | 999,475 | 2,801,305 | 227,605 | — | 14,000 | 4,567,385 |
| Former Chief Development Officer | ||||||||
| Michael Nofi | 67,813 | — | 799,750 | 3,387,209 | 29,887 | — | 0 | 4,284,659 |
| Chief Financial Officer | ||||||||
| Behrad Derakhshan | 520,000 | — | 401,700 | 1,728,428 | 269,100 | — | 14,000 | 2,933,228 |
| Chief Operating Officer | ||||||||
| Joanne Donovan | 530,358 | — | 376,594 | 1,620,389 | 243,965 | — | 14,000 | 2,785,306 |
| Chief Medical Officer | ||||||||
| Alan Russell | 499,580 | — | 376,594 | 1,620,389 | 229,807 | — | 8,479 | 2,734,849 |
| Co-Founder and Chief Scientific Officer | ||||||||
| R. Michael Carruthers | 465,694 | — | 392,707 | 1,500,845 | 214,219 | — | 14,000 | 2,587,465 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kevin Koch | $7,359,546 | $7,601,200 | $3,975,855 | ↓ −241,654 |
| Robert Blaustein | 4,567,385 | — | — | — |
| Michael Nofi | 4,284,659 | — | — | — |
| Behrad Derakhshan | 2,933,228 | 2,896,193 | 1,756,317 | ↑ +37,035 |
| Joanne Donovan | 2,785,306 | 2,924,474 | 1,716,844 | ↓ −139,168 |
| Alan Russell | 2,734,849 | — | — | — |
| R. Michael Carruthers | 2,587,465 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation committee uses equity awards to deliver long-term incentive compensation opportunities to our named executive officers. These equity awards vest or may be earned over multi-year periods, which better serves our long-term value creation goals and retention objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| R. Michael Carruthers | RSU | 17,344 | — | $430,391 |
| Behrad Derakhshan | RSU | 17,344 | — | 430,391 |
| Joanne Donovan | RSU | 17,344 | — | 430,391 |
| Alan Russell | RSU | 17,344 | — | 430,391 |
| Robert Blaustein | RSU | 17,500 | — | 434,263 |
| R. Michael Carruthers | RSU | 26,875 | — | 666,903 |
| Joanne Donovan | RSU | 28,125 | — | 697,922 |
| Alan Russell | RSU | 28,125 | — | 697,922 |
| Robert Blaustein | RSU | 30,000 | — | 744,450 |
| Behrad Derakhshan | RSU | 30,000 | — | 744,450 |
| R. Michael Carruthers | Option | 33,334 | 10.39 | — |
| Behrad Derakhshan | Option | 33,334 | 10.39 | — |
| Alan Russell | Option | 36,667 | 10.39 | — |
| Joanne Donovan | Option | 40,000 | 10.39 | — |
| Michael Nofi | RSU | 43,750 | — | 1,085,656 |
| Kevin Koch | RSU | 53,907 | — | 1,337,702 |
| R. Michael Carruthers | Option | 83,334 | 7.08 | — |
| Joanne Donovan | Option | 83,334 | 7.08 | — |
| Alan Russell | Option | 83,334 | 7.08 | — |
| Kevin Koch | RSU | 87,500 | — | 2,171,313 |
| Behrad Derakhshan | Option | 91,667 | 7.08 | — |
| Kevin Koch | Option | 91,667 | 10.39 | — |
| R. Michael Carruthers | Option | 92,500 | 17.05 | — |
| Behrad Derakhshan | Option | 92,500 | 17.05 | — |
| Joanne Donovan | Option | 92,500 | 17.05 | — |
| Alan Russell | Option | 92,500 | 17.05 | — |
| Robert Blaustein | Option | 96,250 | 13.39 | — |
| R. Michael Carruthers | Option | 147,813 | 13.39 | — |
| Joanne Donovan | Option | 154,688 | 13.39 | — |
| Alan Russell | Option | 154,688 | 13.39 | — |
| Robert Blaustein | Option | 160,000 | 27.39 | — |
| Behrad Derakhshan | Option | 165,000 | 13.39 | — |
| Kevin Koch | Option | 250,000 | 7.08 | — |
| Michael Nofi | Option | 262,500 | 18.28 | — |
| Kevin Koch | Option | 287,500 | 17.05 | — |
| Kevin Koch | Option | 481,250 | 13.39 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Christopher MartinIndependent · Nominating & Corporate Governance | $4,712 | — | $700,000 | — | — | $704,712 |
| Peter Thompson, M.DNot independent | 80,000 | — | 304,477 | — | — | 384,477 |
| Laura BregeIndependent · Audit (Chair) · Compensation | 67,500 | — | 304,477 | — | — | 371,977 |
| Arlene M. MorrisIndependent · Audit · Compensation | 57,500 | — | 304,477 | — | — | 361,977 |
| Badreddin Edris, Ph.DIndependent · Compensation (Chair) | 55,000 | — | 304,477 | — | — | 359,477 |
| Jonathan Root, M.DIndependent · Audit · Nominating & Corporate Governance (Chair) | 55,000 | — | 304,477 | — | — | 359,477 |
| Jonathan C. Fox, M.D., Ph.DIndependent · Audit | 45,000 | — | 304,477 | — | — | 349,477 |
| Kevin Koch, Ph.DEmployee director | — | — | — | — | — | 0 |
| Alan Russell, Ph.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $350,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $364,712 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $364,712 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Edgewise Therapeutics as a peer
Companies that benchmark against EWTX
4 companies name EWTX as a compensation peer
The list of companies that name EWTX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ZNTL Zentalis PharmaceuticalsPTGX Protagonist TherapeuticsKROS Keros TherapeuticsJANX Janux TherapeuticsAVTE Aerovate TherapeuticsPLRX Pliant TherapeuticsRCKT Rocket PharmaceuticalsDYN Dyne TherapeuticsRCUS Arcus BiosciencesDNLI Denali TherapeuticsELVN Enliven TherapeuticsRNA Avidity BiosciencesBEAM Beam TherapeuticsCOGT Cogent BiosciencesIDYA IDEAYA Biosciences Akero BiosciencesKYMR Kymera Therapeutics
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Avidity Biosciences | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 3 | Janux Therapeutics | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 4 | Protagonist Therapeutics | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 5 | Enliven Therapeutics | 2025 | Richard Fair | 38,077 | 0 | 11,880,138 | 0 | 11,918,926 |
| 6 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 7 | Ideaya Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 8 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 9 | Edgewise Therapeutics | 2025 | Kevin Koch | 670,000 | 1,171,625 | 5,041,621 | 462,300 | 7,359,546 |
| 10 | Beam Therapeutics | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 11 | Pliant Therapeutics | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 12 | Denali Therapeutics | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 13 | Rocket Pharmaceuticals | 2025 | Gaurav Shah | 671,076 | 806,751 | 1,613,377 | 403,048 | 3,510,241 |
| 14 | Keros Therapeutics | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 15 | Dyne Therapeutics | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 16 | Zentalis Pharmaceuticals | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
| — | Aerovate Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Edgewise Therapeutics | not disclosed | not disclosed | not disclosed | Alpine |
| Aerovate Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Avidity Biosciences | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine |
| Beam Therapeutics | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Denali Therapeutics | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dyne Therapeutics | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Enliven Therapeutics | not disclosed | Option 100 | not disclosed | not disclosed |
| Ideaya Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Keros Therapeutics | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Pliant Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Protagonist Therapeutics | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Rocket Pharmaceuticals | not disclosed | not disclosed | not disclosed | Semler Brossy |
| Zentalis Pharmaceuticals | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 87,055,111 | 3,491,326 | 577,257 | 96.14% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 96.14%a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (35 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kevin Koch. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 7,359,546. View filing ↗
- Section 01, Robert Blaustein. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 4,567,385. View filing ↗
- Section 01, Michael Nofi. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 4,284,659. View filing ↗
- Section 01, Behrad Derakhshan. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 2,933,228. View filing ↗
- Section 01, Joanne Donovan. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 2,785,306. View filing ↗
- Section 01, Alan Russell. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 2,734,849. View filing ↗
- Section 01, R. Michael Carruthers. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 2,587,465. View filing ↗
- Section 08, Christopher Martin. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 704,712. View filing ↗
- Section 08, Peter Thompson, M.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 384,477. View filing ↗
- Section 08, Laura Brege. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 371,977. View filing ↗
- Section 08, Arlene M. Morris. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 361,977. View filing ↗
- Section 08, Badreddin Edris, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 359,477. View filing ↗
- Section 08, Jonathan Root, M.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 359,477. View filing ↗
- Section 08, Jonathan C. Fox, M.D., Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 349,477. View filing ↗
- Section 08, Kevin Koch, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Alan Russell, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-05. Item 5.07 · say-on-pay result. As reported: 96.14% (votes for as printed: 87,055,111). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 364,712 + equity 0 + all other 0 = 364,712, summed across the director compensation table rows.
- Cogent Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. View filing ↗
- Avidity Biosciences, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Avidity Biosciences's own proxy. As printed: 14,176,480. View filing ↗
- Janux Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. View filing ↗
- Protagonist Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics's own proxy. As printed: 12,871,506. View filing ↗
- Enliven Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Enliven Therapeutics's own proxy. As printed: 11,918,926. View filing ↗
- Arcus Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. View filing ↗
- Ideaya Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences's own proxy. As printed: 9,512,640. View filing ↗
- Kymera Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. View filing ↗
- Edgewise Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Edgewise Therapeutics's own proxy. As printed: 7,359,546. View filing ↗
- Beam Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Beam Therapeutics's own proxy. As printed: 5,818,525. View filing ↗
- Pliant Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics's own proxy. As printed: 5,462,901. View filing ↗
- Denali Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
- Rocket Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. View filing ↗
- Keros Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. View filing ↗
- Dyne Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics's own proxy. As printed: 2,076,868. View filing ↗
- Zentalis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. View filing ↗